Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Vandetanib Advantages in Medullary Thyroid Cancer

March 15th 2011

Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

March 15th 2011

Dr. Langmuir Discusses Vandetanib Clinical Trials

March 15th 2011

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.

Dental Care Steps to Prevent and Treat Osteonecrosis of the Jaw

March 14th 2011

Everyone can benefit from good oral hygiene, but people with cancer need to pay particular attention to their dental health

The Emperor of All Maladies: Documenting Cancer's Long Reign

March 12th 2011

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

FDA Approves Zactima

March 9th 2011

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

Dr. Pearlstone on Technological Challenges

March 8th 2011

John Theurer Cancer Center Opens New Comprehensive Facility

March 4th 2011

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Net Guides: Oral Cancer

December 16th 2010

Useful Online Resources and Clinical Trials for Oral Cancer

ASCO 2010: Opaxio Highly Active in Esophageal Cancer

August 14th 2010

A drug that delivers paclitaxel in a novel way has yielded favorable results in a phase II trial of patients with advanced esophageal cancer, prompting the company developing the drug to plan a phase III trial.

ASCO 2010: Vandetanib Extends PFS in Medullary Thyroid Carcinoma

August 14th 2010

Data from the phase III ZETA trial show that vandetanib (Zactima), a selective tyrosine kinase inhibitor, significantly slows the progression of advanced medullary thyroid carcinoma

The RapidReporter: Recent Developments, Findings, and Research in Head and Neck Cancer

July 6th 2010

Identifying head and neck cancer patients who possess the FcyR genotype may help predict whether they will respond to monoclonal antibodies, which work by killing cancer cells bearing epidermal growth factor receptors (EGFR) on their surface.

50th Annual Meeting of the American Society of Hematology

January 27th 2009

Highlights from the 50th Annual Meeting of the American Society of Hematology.